Dataset for studies on engineered hydrocortisone for treating orthotopic colon cancer

Published: 11 June 2020| Version 1 | DOI: 10.17632/4tpm8whg3b.1
Rajkumar Banerjee


This dataset provides the details of the experimental data submitted in main text as well as in supplementary information for the studies related to depiction of systemic potential of chemically engineered hydrocortisone molecule for the treatment of colon cancer. We find that cationic lipid-conjugation with hydrocortisone infused a special property in the hydrocortisone derivative. Initially, the molecule acted as a potent anticancer molecule but we could not comprehend its further behaviour before this study is accomplished. We find that the molecule dissolved in minimum ethanol when dispersed in water by fast injection method, assumed self-aggregation, while maintaining positive surface charge and distinct hydrodynamic size. This enabled it to carry anticancer entities such as small molecule drugs and genes. The aggregate showed multinodal properties of not only carrying multiple cargoes but it showed a unique cancer cell-selective uptake and nuclear localization. This cancer cell-selective nuclear localisation led to down-regulation of drug metabolizable factors, thereby inducing drug sensitization in cancer cells. Our study in overall indicate that hydrocortisone, the natural glucocorticoid if properly engineered can make a viable therapeutic biomaterial for the treatment of cancer by way of sensitizing cancer cells to drugs and by cancer cell-selective delivery of both anticancer drug and gene.



Indian Institute of Chemical Technology


Colon Cancer, Glucocorticoid Receptor, Targeted Therapy, Sensitization